Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy

Acta Neurologica Belgica

Volumn 109, Issue 2, 2009, Pages 120-126

  Kocer, Belgin ^a   Sucak, G ^a   Kuruoglu, R ^a   Aki, Z ^a   Haznedar, R ^a   Ince Erdogmus, N ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Cumulative dose; Electrophysiological findings; Multiple myeloma; Neurotoxicity; Thalidomide neuropathy

Indexed keywords

THALIDOMIDE;

AGE DISTRIBUTION; ARM MUSCLE; ARTICLE; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; ELECTROPHYSIOLOGY; HUMAN; LEG MUSCLE; MULTIPLE MYELOMA; MUSCLE ACTION POTENTIAL; NERVE CONDUCTION; NERVE POTENTIAL; PERIPHERAL NEUROPATHY; PERONEUS MUSCLE; PERONEUS NERVE; SCORING SYSTEM; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SEX DIFFERENCE; ULNAR NERVE;

EID: 67849119328     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Apfel SC, Zochodne DW. Thalidomide neuropathy:too much or too long? Neurology. 2004;62(12):2158-2159.
2. Briani C, Zara G, Rondinone R, Libera SD, Ermani M. et al. Thalidomide neurotoxicity:prospective study in patients with lupus erythematosus. Neurology. 2004;62(12):2288-2290. (Pubitemid 38787790)
3. Cavaletti G, Beronio A, Reni L, Ghiglione E, Schenone A. et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology. 2004;62(12):2291-2293.
4. Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med. 2006;354:1076-1078.
5. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E. et al. Thalidomide-induced neuropathy. Neurology. 2002;59(12):1872-1875.
6. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol. 1984;120(3):338-341.
7. Giannini F, Volpi N, Rossi S, Passera S, Fimiani M. et al. Thalidomide-induced neuropathy: A ganglionopathy? Neurology. 2003;60(5):877-878.
8. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Semin Oncol. 2006;33(1):15-49.
9. Isoardo G, Bergui M, Durelli L, Barbero P, Boccadoro M. et al. Thalidomide neuropathyxlinical, electrophysiological and neuroradiological features. Acta Neurol Scand. 2004;109(3):188-193. (Pubitemid 38270874)
10. Lagueny A, Rommel A, Vignolly B, Taieb A, Vendeaud-Busquet M. et al. Thalidomide neuropathy:an electrophysiologic study. Muscle Nerve. 1986;9(9):837-844.
11. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB. et al. Development of neuropathy in patients with myeloma treated with thalidomide:patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24(27):4507-4514. (Pubitemid 46630990)
12. Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol. 1994;130(1):66-69. (Pubitemid 24032286)
13. Oh SJ. Clinical Electromyography. In:Nerve Conduction Studies. 2nd edition. Baltimore, Williams & Wilkins; 1993.
14. Plasmati R, Pastorelli F, Cavo M, Petracci E, Zamagni E. et al. Neuropathy in multiple myeloma treated with thalidomide:A prospective study. Neurology. 2007;69(6):573-581.
15. Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D. et al. Neurological toxicity of long-term (> 1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005;74(3):212-216. (Pubitemid 40278490)
16. Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin. Neurol. 2005;18(5):574-580.
17. Vital A. Paraproteinemic neuropathies. Brain Pathol. 2001;11(4):399-407.